

FLYING MONKEY CAPITAL CORP.
Suite 2300 - 1066 West Hasting Street
Vancouver, BC V6E 3X2

NEWS RELEASE

January 6, 2016

TSXV Symbol: FMK.P

Flying Monkey Capital Corp. Announces Proposed Qualifying Transaction

Vancouver, British Columbia. Flying Monkey Capital Corp. ("FMCC" or the "Company"), a capital pool company, is pleased to announce that it has entered into an agreement in principle dated December 14, 2015 (the "LOI") for the acquisition (the "Proposed Transaction") of HUMN Pharmaceuticals Inc. ("HUMN"), a private company incorporated under the Federal Laws of Canada. Upon completion of the Proposed Transaction, the business of HUMN will become the business of FMCC.

FMCC is a capital pool company and the Proposed Transaction is intended to constitute the Company's qualifying transaction ("Qualifying Transaction") under Policy 2.4 of the TSX Venture Exchange (the "Exchange"). The Proposed Transaction is an arm's length transaction and accordingly will not require the approval of FMCC's shareholders.

About HUMN

HUMN Pharmaceuticals Inc. ("the Company") was incorporated on December 3, 2008 under the Canada *Business Corporations Act*. Since incorporation HUMN has developed, tested and consummated a suite of pharmaceuticals focused on pain relief that achieved the base objectives of being effective and safe to use.

HUMN's mission is to develop highly effective and clinically proven solutions, devoid of adverse side effects and dependency free, for ailments and conditions that affect a very large percentage of the global population.

HUMN introduced the initial product TPR20, to the marketplace. Market acceptance was considered a success with anyone trying the product becoming not only an ongoing user but an ambassador for the product.

More surprising was the different uses that people found for TPR20. Consequently, HUMN has now received regulatory approval to sell four different products in Canada. Health Canada has issued each a DIN (Drug Identification Number). The products are also approved for sale in the United States. HUMN is currently applying for DIN's for further products that it has developed.

In Canada, TPR20 is carried by the London Drugs, Rexall and Jean Coutu pharmacy chains as well as other recognized drug stores. These total approximately 1,500 pharmacy locations.

HUMN has a five (5) year Distribution Agreement with Alliance Healthcare (a division of Walgreens Boots Alliance Inc.) of the United Kingdom which becomes active once HUMN receives U.K. regulatory approval. Alliance has 14,400 account locations in the U.K. and the group has over 189,000 accounts worldwide.

The Company has raised over \$ 2,500,000 since incorporation to finance its operations.

HUMN has two Shareholders who own more than 10% of HUMN's common shares. Blair J. McInnes of Winnipeg, Manitoba owns 25.25% and Stanton Hill of Calgary, Alberta owns 27.71%

As of its fiscal year end of September 30, 2015, HUMN owns \$202,378 of Current Assets that are part of its \$215,904 Total Assets. HUMN has Current Liabilities of \$64,979 and shareholder loans of \$149,027. It had revenue of \$127,468 and gross operating income of \$48,736. This was offset by sales and marketing, and general and administrative expenses totaling \$474,012 for a net loss of \$425,276.

Terms of the Proposed Transaction

Pursuant to the terms of the LOI, FMCC will acquire HUMN in exchange for a maximum of 30,000,000 post-consolidated common shares of FMCC (the "Transaction Shares") as set forth below. The Transaction Shares will be issued to the shareholders of HUMN pursuant to exemptions from the registration and prospectus requirements of applicable securities laws. The Transaction Shares will be subject to resale restrictions as required under the applicable securities legislation and the Exchange and will also be subject to escrow restrictions as required by the Exchange.

In connection with the Proposed Transaction, the Company will change its name to a name acceptable to HUMN and to applicable regulatory authorities.

It is expected that upon completion of the Proposed Transaction, the resulting issuer (the "Resulting Issuer") will be listed as a Tier 2 Diversified Industries Issuer on the Exchange.

Completion of the Proposed Transaction is subject to a number of conditions, including execution of a definitive agreement, completion of satisfactory due diligence, receipt of applicable regulatory approvals, Name Change, and Share Consolidation. There can be no assurance that the Proposed Transaction will be completed as proposed or at all.

Name Change and Consolidation

Prior to the completion of the Proposed Transaction, FMCC will complete a share consolidation on a 3 to 1 basis (three pre-consolidated shares for one post-consolidated share) (the "Share Consolidation") and a name change, expected to be to "HUMN Pharmaceuticals Inc."

Under the terms of the LOI, FMCC will acquire all of the issued and outstanding common shares of HUMN in exchange for the issuance of common shares of FMCC on the basis of one post-consolidated common share of FMCC for every one HUMN share held. There are currently 27,840,000 HUMN common shares issued. This will result in FMCC issuing an aggregate of 27,840,000 post-consolidated common shares to acquire HUMN. Upon completion of the Proposed Transaction, HUMN will become a wholly-owned subsidiary of the Company.

There are currently 5,612,001 FMCC common shares issued and outstanding, as well as 200,000 common share purchase warrants and 561,200 stock options of FMCC outstanding. Upon completion of the Share Consolidation, the Proposed Transaction and including those securities issued in the transactions discussed below, there are expected to be a minimum of 29,710,667 and a maximum of 30,870,667 post-consolidated FMCC common shares issued and outstanding, 971,667 post-consolidated share purchase warrants, and 187,067 post-consolidated stock options of FMCC.

The present directors of FMCC will enter into a voting trust agreement with the Chairman of HUMN giving the Chairman the right to vote their shares for a term of four years.

Upon completion of the Proposed Transaction, all FMCC common shares to be issued to holders of HUMN shares upon completion of the Proposed Transaction may be subject to resale restrictions under applicable securities laws and the policies of the Exchange, as applicable. In addition, all common shares held by Principals of FMCC (as such term is defined in the policies of the Exchange) will be held in escrow in accordance with the policies of the Exchange.

Proposed Private Placement

Prior to or concurrent with the Closing of the Proposed Transaction, HUMN will complete a financing (debt or equity) for a minimum of \$ 500,000 at \$ 0.50 per share and a maximum of \$ 1,500,000 at \$ 1.00 per share which will be sufficient to provide the Resulting Issuer with adequate working capital. All securities issued pursuant to the private placement will be subject to a hold period of four months and one day.

The proceeds raised will be used to fund the costs associated with completing the Proposed Transaction, introduction of further products to the marketplace and the commencement of television advertising.

FMCC/HUMN will pay commission on proceeds raised commensurate with industry norms. It is not known if any securities company will be engaged to assist with fund raising activities.

Sponsorship

FMC will choose a suitable Canadian securities company to act as sponsor in connection with the Proposed Transaction. Any agreement to sponsor should not be construed as any assurance with respect to the merits of the transaction or the likelihood of completion.

Conditions Precedent

The parties' obligations to complete the Proposed Transaction are subject to the satisfaction of customary conditions precedent including:

- (a) all necessary approvals of the Exchange and all other regulatory authorities and third parties to the Acquisition and the private placement being obtained;
- (b) the completion of the Name Change and Share Consolidation on the terms set forth above; and
- (c) the parties being satisfied with the results of their respective due diligence reviews in connection with the Proposed Transaction.

Directors, Officers and Insiders of Resulting Issuer

On completion of the Proposed Transaction, the directors, officers and insiders of the resulting issuer are anticipated to be:

Blair J. McInnes – Founder, Director, Chairman, President.

Mr. McInnes has been exclusively involved in the health and wellness industry for the last 10 years. Through his prior business activities, he has established a global network of business colleagues and has participated in and been an advisor to a number of successful start-up entities. For the last 7 years he has led HUMN in the development of the formulations, testing of the product efficacies and assessing the most efficient methodology for introduction of the company products to the distribution channels in order to maximize market penetration.

Mr. McInnes has had a successful career in both manufacturing and sales and has established a wide network of sales associates. He has also served on the Board of Directors of public companies. He is adept at assembling top quality management teams and effectively leading them towards an established vision for the company.

Adam Topp – Director and CEO.

Mr. Topp was the Chief Operating Officer of the Winnipeg Health Sciences Centre, an operating division of the Winnipeg Regional Health Authority from 2007 to 2012. Within the WRHA he was also responsible for a number of Regional programs including Child Health, Critical Care, Diagnostic Imaging, Respiratory Therapy and Clinical Engineering.

Prior to the WRHA, Mr. Topp was a Senior Associate Consultant with Hay Group Health Care Consulting, from 2003 to 2007, where he focused on health care policy development and analysis, hospital operations and management and health services planning. A large component of his consulting practice consisted of issues associated with private healthcare delivery and purchasing behavior and influences.

He received his degrees from McMaster University and his MBA majors were Health Services Management and Marketing. He is currently a doctoral candidate at the University of Toronto. Mr. Topp serves on the Boards of a number of health care related entities, has been lead consultant on numerous high level and complex health care related assignments and has published several papers related to the industry.

Paul L. (Les) Hammond – Director and CFO.

Mr. Hammond has been with HUMN since March 2012 He has extensive experience in international corporate finance related to mergers and acquisitions and has dealt with the major capital markets in New York, London and Toronto. He is a graduate of Simon Fraser University (Economics and Commerce) and a Chartered Accountant. He has held senior executive operating positions in telecommunications, computer retailing, real estate development, financial services, brewery operations, transportation and mining. These projects were conducted in Europe, North and Central America, the United Kingdom, Western Africa, New Zealand, South East Asia and China.

For the past 35 years he has acted as an investment banker assisting companies with acquisitions, financing, sales and distribution, turnarounds, improvement of management depth, corporate governance and reporting and compliance issues.

David Smalley – Director and Corporate Secretary

Mr. Smalley is a current Director of FMCC. Upon completion of the Proposed Transaction he will remain as a Director and become Corporate Secretary of the Resulting Issuer. Mr. Smalley is the Principal of David Smalley Law Corporation where he practices Corporate and Securities law. He has been an officer and director of numerous public companies for 20 years as well as serving as chair of numerous audit and governance committees.

Brian Herron, Director and U.K. Managing Director

Mr. Herron has over 30 years' experience in distribution logistics within the pharmaceutical and health products industry, primarily in Europe. His responsibilities entailed fleet management, warehousing and shipping and major customer relationship management. He has functioned as an Operations Manager, a Distribution Director and a Regional Director for a multi-national organization.

Connie Clerici – Director.

Ms. Clerici has over 30 years' experience in the health care field and currently employs over 750 healthcare professionals in Ontario's homecare industry. She brings a unique perspective to potential markets and product development. Ms. Clerici was an Advisory Board member in 2011 for Women of Influence and a 2011 Entrepreneurship Council member with the Richard Ivey School of Business.

Gail Halko – Director.

Ms. Halko is founder and an owner of Grand Medicine Health Services. She founded Grand Medicine in 1999 with the goal of redefining a pharmacy's interactions with clients moving away from the traditional commodity based model of the industry. The Grand Medicine Group is ISO certified and operates three pharmacies, a medical supply company, a wholesale/distribution centre, and a diabetes education centre. Grand Medicine was awarded the prestigious Canadian Pharmaceutical Associations' Patient Care Achievement Award for Innovation in 2012.

Art Pemberton, Chief Operating Officer,

Mr. Pemberton has a successful 30+ year record of strategic, executive/senior management and consulting roles with both private and public national corporations in North America. He is an experienced leader in operations, information technology, human resources, legal and finance in retail distribution and manufacturing. He has successfully led 2 of Canada's dominant, vertically-integrated retail operations combined with North American wholesale sales and distribution.

Stanton Hill – Insider

Mr. Hill has had a successful career as an entrepreneur – primarily as an inventor and developer of products. He is responsible for developing over 150 eco-friendly products that are used extensively globally for major brand companies. He has led the strategy development and fabrication of testing and solution oriented equipment. He has consulted on behalf of major multinational companies. The extent of his world-wide activity has provided him with a network of friends and business associates. He has a wealth of knowledge and experience in starting companies and developing them to their full potential. His expertise continues to be utilized on behalf of international companies.

Trading Halt

Upon the execution of the LOI, the shares of FMCC were halted and it is expected that they will remain halted until completion of the Qualifying Transaction.

General

Completion of the Proposed Transaction is subject to a number of conditions, including but not limited to, Exchange acceptance. Where applicable, the Proposed Transaction cannot close until the required shareholder approval is obtained. There can be no assurance that the Proposed Transaction will be completed as proposed or at all.

Investors are cautioned that, except as disclosed in the filing statement or other disclosure document to be prepared in connection with the Proposed Transaction, any information released or received with respect to the Proposed Transaction may not be accurate or complete and should not be relied upon. Trading in the securities of a capital pool company should be considered highly speculative.

The TSX Venture Exchange Inc. has in no way passed upon the merits of the Proposed Transaction and has neither approved nor disapproved the contents of this press release.

Other Information and Updates

FMCC and HUMN will continue to provide further details in respect of the Proposed Transaction, in due course, by way of news releases.

For further information please contact:

David W. Smalley, Director
Flying Monkey Capital Corp.
Phone: (604) 684-4535

Statements in this press release regarding FMCCs business which are not historical facts are "forward-looking statements" that involve risks and uncertainties, such as terms and completion of the Proposed Transaction. Since forward-looking statements address future events and conditions, by their very nature, they involve inherent risks and uncertainties. Actual results in each case could differ materially from those currently anticipated in such statements.